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LETTERS TO THE EDITOR
Regarding “Impact of diabetes mellitus on outcomes
of superficial femoral artery endoluminal
interventions”
In a recent study, Bakken et al concluded that endoluminal
therapy for superficial femoral artery (SFA) occlusive disease yields
lower assisted patency rates and higher restenosis rates for those
presenting with claudication and more advanced diabetes.1 In
those with critical limb ischemia, limb salvage rates are lower in
diabetic patients, despite comparable patency rates to non-diabetic
patients. These results are of great importance as a significant
portion of any modern vascular practice consists of diabetic pa-
tients.
We recently analyzed our results for endoluminal therapy with
expanded polytetrafluorethylene (ePTFE)-covered endografts for
superficial femoral artery (SFA) occlusive disease (mix of claudi-
cants and critical limb ischemia). Stents with ePTFE-endo-lining
were developed to reduce the rate of in-stent stenosis based on its
characteristics of biocompatability observed in previous studies
using ePTFE bypass grafts. In our prospective analysis of 96
patients during 2-years follow-up, we observed no difference in
primary patency rates between diabetics (66%, n  33) and non-
diabetics (74%, n  63). However, the assisted patency rates were
lower in diabetics (68%) compared to non-diabetics (86%, P 
.02). Also in ePTFE-covered endografts, diabetes seems to confer
an increased risk for restenosis and so a significantly reduced
cumulative patency rate.
The authors separated their diabetic population into insulin-
dependent and non-insulin-dependent diabetic patients, assuming
that those taking more insulin had more severe diabetes. However,
insulin dependency seems to not be a very good way to stratify
diabetic patients to their diabetes severity. A more biological based
method is the analysis of tissue advanced glycation endproducts
(AGEs) accumulation. AGEs are a heterogeneous group of com-
pounds formed by the reaction of sugars (hyperglycemia) with
proteins, lipids (hyperlipidemia), and oxidative stress (eg, from
smoking). Assessment of tissue AGE accumulation serves as a
measure of cumulative metabolic stress and protein damage, and so
reflects diabetes severity (Fig).2 Furthermore, AGEs are related to
long-term complications in diabetes, including peripheral artery
occlusive disease and stent patency.3 AGEs not only play a major
role in the development of (chronic) atherosclerosis, but also
contribute to the formation of neointimal hyperplasia following
acute vessel wall injury. In diabetic patients receiving cardiac stents,
an elevated level of serum AGEs appears to be an independent risk
factor for the development of angiographic re-stenosis.4
The authors furthermore observed lower limb salvage rates in
diabetic patients compared to non-diabetic patients with critical
limb ischemia, despite equivalent patency rates for both groups.
We have recently shown in diabetic patients that AGE accumula-
tion is related to the severity of diabetic neuropathy as well as the
severity of diabetic foot ulceration.5 We and others have shown
that AGEs predict the development and progression of microvas-
cular complications, such as diabetic neuropathy.6 Finally, block-
age of AGEs accelerates wound closure. So, AGE accumulation
may play a role in diabetic foot ulceration by its effects on neurop-
athy, vascular disease, and delayed wound repair.
In conclusion, lower patency rates and lower limb salvage rates
are observed in diabetic patients with SFA occlusive disease. The
assessment of AGE accumulation may serve as a simple measure for
diabetes severity. Furthermore, AGE levels are strongly related to
stent patency rates and foot ulceration in diabetes.
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Reply
We appreciate the comments of Meerwaldt et al on our recent
article. We did not use a primary stenting policy in our study
because the literature and current level 1 evidence do not support
their use. The use of covered stents has several theoretic advan-
tages, but their use is not supported by adequately powered
randomized clinical trials. Irrespective of these concerns, the anec-
dotal data presented on covered stents further supports our find-
Fig. Advanced glycation endproducts (AGEs) show the cumula-
tive damage to proteins by hyperglycemia, hyperlipidemia, oxida-
tive stress, and decreased renal clearance of AGE-precursors. AGE
accumulation leads to atherosclerosis and microvascular complica-
tions through their effect on extracellular proteins (eg, collagen
and lipoproteins) and by their interaction with specific receptors,
inducing inflammation and endothelial dysfunction.3
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